Bisphosphonate induced osteochemonecrosis of the jaws: An ounce of prevention may be worth a pound of cure

Special Care in Dentistry

Volumn 26, Issue 1, 2006, Pages 8-12

  Hellstein, John W ^a   Marek, Cindy L ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bis phossy; Bisphosphonate; Jaw; Osteochemonecrosis; Prevention; Protocol

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; NITROGEN;

ARTICLE; BONE NECROSIS; BONE TUMOR; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DENTAL CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; RISK MANAGEMENT;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENTAL CARE FOR CHRONICALLY ILL; DIPHOSPHONATES; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; NITROGEN; OSTEONECROSIS; OSTEOPOROSIS; RISK MANAGEMENT;

EID: 33644756489     PISSN: 02751879     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1754-4505.2006.tb01503.x     Document Type: Article

References (17)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 Sep;61(9):1115-7.
2. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005 Feb;34(2):120-3.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004 May;62(5):527-34.
4. Drug Facts and Comparisons. St. Louis: Wolters Kluwer Health; 2005.
5. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9 Suppl 2:S66-80.:S66-S80.
6. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995 Sep;58(3):288-98.
7. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3 Suppl 3:S13-6.:S13-S16.
8. Chustecka Z. More than 50 cases of jaw osteonecrosis with alendronate. Rheumawire 2005 June 17 Available from: URL: http://www.jointandbone.org/ viewArticle.do? primaryKey=508383
9. Avanstar Publications. Top 200 brand-name drugs by units in 2004. Drug Topics 149[5], 26. 3-7-2005. Ref Type: Journal (Full)
10. Novartis Pharmaceuticals Corporation. Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw. Federal Drug Administration 2005 February 1 Appendix 11 Available from: URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_02_12-Novartis- Zometa-App-11.htm
11. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005 May;63(5):682-9.
12. Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg 2004 Dec;62(12):1563-5.
13. Gargiulo AW, Wentz FM, Orban B. Dimension and relations of the dentogingival junction in humans. J Periodontol 32, 163-169. 1961. Ref Type: Journal (Full)
14. Felippe LA, Monteiro JS, Vieira LC, Araujo E. Reestablishing biologic width with forced eruption. Quintessence Int 2003 Nov;34(10):733-8.
15. Yeh S, Andreana S. Crown lengthening: basic principles, indications, techniques and clinical case reports. NY State Dent J 2004 Nov;70(8):30-6.
16. Joly JC, de Lima AF, da Silva RC. Clinical and radiographic evaluation of soft and hard tissue changes around implants: a pilot study. J Periodontol 2003 Aug;74(8):1097-103.
17. Padbury A, Jr., Eber R, Wang HL. Interactions between the gingiva and the margin of restorations. J Clin Periodontol 2003 May;30(5):379-85.